Health care stocks were edging higher premarket Monday as the Health Care Select Sector SPDR Fund (XLV) was up 0.5% and the iShares Biotechnology ETF (IBB) recently advanced by 0.9%.
Cassava Sciences (SAVA) shares plunged by 84% after the company said its late-stage trial of simufilam in mild-to-moderate Alzheimer's disease did not meet the co-primary endpoints of cognitive and functional improvement.
Biohaven (BHVN) shares fell past 10% after the company said a study of its experimental drug for spinal muscular atrophy did not achieve a "statistically significant difference" compared with placebo and standard of care at 48 weeks.
Alnylam Pharmaceuticals (ALNY) shares were up over 2% after the company said the US Food and Drug Administration has accepted its supplemental new drug application for vutrisiran, an investigational RNAi therapeutic for the treatment of ATTR amyloidosis with cardiomyopathy.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。